Ark Therapeutics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Private, Subsidiary
- Established
- 2018-04-30
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:2
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence
Phase 3
Terminated
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- Ark Therapeutics Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT00895479
- Locations
- 🇺🇸
Long Beach VA Healthcare System, Long Beach, California, United States
🇺🇸Four Rivers Clinical Research Inc, Paducah, Kentucky, United States
🇺🇸Baton Rouge General Hospital, Baton Rouge, Louisiana, United States
News
No news found